Ajanta Pharma is a specialty pharmaceuticals formulation company with a well-diversified Branded Generics business spread across India, Asia, and Africa as also US Generics and Institutional business in Africa. In Branded Generics business, the Company has a strong chronic-focused product portfolio led by a first-to-market strategy and front-end presence which helps it outgrow the market. The Company is committed to investing in R&D for product innovations to meet the unmet medical needs by filling identified gaps.

Business area of the company

The company is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages. Its business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales. It has designed customised basket of products for each of these markets and serve wide range of therapeutic segments like Anti-Biotic, Anti-Malarial, Anti-Diabetic, Cardiology, Gynecology, Orthopedics, Pediatric, Respiratory & General Health products.

Products of the company

• Tablets
• Capsules
• Sterile eye drops
• Dry powder suspension
• Liquids
• Injectables
• Ointments
• Creams

Awards and accreditations

• 2011: Gold Trophy for Quality Excellence from Indian Drug Manufacturer's Association.
• 2015: Listed in Top 100 Companies of Asia by Bio Spectrum Asia, Ranked 76th.
• 2015: Listed in Fortune India Next 500, being 3rd largest wealth creator during last 5 years, Ranked 20th in Net Profit and 182nd in Sales.
• 2015: Fastest wealth creator in last 5 years as per a study by Motilal Oswal.
• 2016: Listed in ‘Fastest Growing Company in India’ and Ranked 21st by Outlook Business Magazine.
• 2017: Ajanta listed among fastest growing pharma company, ranked 11th in revenue by Businessworld.
• 2017: Listed among Out Performers List of Outlook Business, ranked 1st Among Stock Return.
• 2017: Listed among ‘Forbes India Super 50 Companies’ for the 3rd year in a row.
• 2017: Listed in BT 500 ranked 148th in Market Capitalisation, 327th in sales & 102nd in Profit.
• 2017: Ranked 186th in Next Super 100 companies by Business India.
• 2017: Listed as Fastest Wealth Creator for the 3rd year in a row by Motilal Oswal.
• 2018: Listed in Fortune 500 list of Indian companies Ranked 3rd in wealth creation.
• 2018: Top Export Performer Award' by the Federation of Indian Export Organisations.
• 2021: Listed in Fortune 500 list of Indian companies. Ranked 379th in Revenue Generation.
• 2022: Ajanta wins Excellence in Packaging Developed in India & Packaging Team of the Year at India Packaging Awards 2022.
• 2022: Ajanta wins 'Maharashtra State Best Employer Brand Awards 2022' in Pharma sector.
• 2022: Ajanta Pharma awarded 'India's Best Managed Companies' for 2022 by Deloitte.
• 2023: Ajanta wins Times Ascent Global Best Employer Brands 2023.
• 2023: Ajanta wins 'Outstanding Export Performance Award' from Pharmexcil in 'Formulation' category.
• 2024: Ajanta wins 'Golden Peacock Business Excellence Award 2024' in the Pharma sector.
• 2024: Ajanta wins 'SKOCH ESG Award 2024' for Clean & Green Energy Utilisation.
• 2024: Ajanta wins 'Pharma Supply Chain Champion' Award in Mid Sized firms category.
• 2024: Ajanta wins 'Apex India Green Leaf Platinum Award 2023 for Sustainability' in Pharma sector.
• 2024: Ajanta's Paithan facility recognized with 'Apex India Safe Workplace Gold Award 2023' in Pharma sector.
• 2024: Ajanta's Dahej Facility wins Silver Medal from National Awards for Manufacturing Competitiveness (NAMC).
• 2024: Ajanta wins Packaging Team of the Year at India Packaging Awards 2024.
• 2024: Ajanta wins 'Outstanding Export Performance Award' from Pharmexcil in 'Formulation' category.
• 2024: Ajanta's Dahej facility recognized with 'Best Manufacturing Facility Award' at the Pharma Manufacturing & Automation Excellence (PM & AE) Awards.
• 2024: Ajanta's Paithan facility presented with one Platinum and two Silver Kaizen awards at the 50th CII National Kaizen Competition.
• 2024: Ajanta's Guwahati Facility presented with 'Best Labour Law Compliant Establishment' by Government of Assam.
• 2024: Ajanta wins ‘Star Champion’, ‘Star Challenger’, and ‘Jury Challenger’ awards at the next level of the Kaizen Competition.
• 2025: Ajanta wins Pharma Supply Chain Award for ‘Best-in-Class Inventory Planning’.
• 2025: Ajanta wins 'Pharma Company of the Year' & 'Excellence in Supply chain, Logistics and Distribution' at the Economic Times Re-Pharma Awards.
• 2025: Ajanta presented with 'Excellence in Pharma Research & Development Award' at the World HRD Congress.
• 2025: Ajanta's Paithan facility clinched Gold in Alarm Category, Silver in Control Category, and Silver in Shutdown Category at CII National Poka Yoke Competition.
• 2025: Ajanta recognized by Ethiopian Pharmaceutical Supply Service (EPSS), Ethiopia, for ensuring speedy delivery of anti-malarial medicines.
• 2025: Ajanta wins Platinum in Breakthrough Category, Gold in Innovative & Restorative Categories, and Silver in Renovative Category at 51st CII National Kaizen Competition.
• 2025: Ajanta presented with ‘Industry 4.0 Initiatives’ and ‘Environmental Consciousness’ awards by Chamber of Marathwada Industries & Agriculture (CMIA).
• 2025: Ajanta's Paithan facility wins Pharma Quality Excellence Awards for ‘Good Documentation Practices’ and ‘QMS Integration’.
• 2025: Ajanta's Pithampur facility presented with 'Environmental Excellence Award' by Government of Madhya Pradesh.
• 2025: Ajanta wins ‘Excellence in Supply Chain & Logistics Packaging’ and ‘Packaging Team of the Year’ at India Pharma Packaging Awards 2025.
• 2025: Ajanta's Guwahati Facility wins Gold Medal at National Awards for Manufacturing Competitiveness (NAMC).

Major events and milestones

• 1973: Ajanta started with re-packing of generic products.
• 1979: Launched branded OTC (Over the Counter) products.
• 1979: First Manufacturing Facility set up in India- (Chikalthana).
• 1986: Started production at second manufacturing facility in India-(Paithan).
• 1989: Launched block buster OTC product '30+' in India.
• 1992: Foray in international market.
• 1995: Established subsidiary in Mauritius with manufacturing facility.
• 2000: Got listed on National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).
• 2005: Strategic shift from OTC to Innovative Specialised Prescription Products in Ophthal, Dermatology & Cardiology.
• 2007: Set-up dedicated fully equipped R&D facility in Mumbai.
• 2009: Bought a manufacturing facility at Chitegaon to fuel the company's growth.
• 2009: API facility set up in Waluj for captive consumption.
• 2009: First Generic Company in the world to get WHO Geneva Pre-qualification for Anti-Malarial Drug.
• 2010: Entered Philippines market with unique product portfolio through Ajanta Pharma Philippines Inc.
• 2011: Emerged as a strong speciality player in domestic market in Ophthalmology, Dermatology and Cardiology with many brands holding leadership positions.
• 2012: Ranked among the Top 10 Pharma companies in Franco Africa.
• 2013: Began Sales in the USA.
• 2014: Second Dedicated R&D centre set up in Kandivli for India and Emerging Markets.
• 2014: Inaugurated a New Facility in Dahej, Bharuch, Gujarat, India.
• 2015: Launch of Montelukast lR Tablets and Chewable Tablets.
• 2015: Launch of Montelukast Sodium Oral Granules.
• 2016: USFDA Approval for Almotriptan Malate Tablets.
• 2017: Inaugurated & commissioned first phase at a New Facility in Guwahati, Assam, India.
• 2017: Dahej facility receives successful US FDA approval.
• 2017: Launch of Eletriptan Hydrobromide tablets in US market. 
• 2017: USFDA approval for Entacapone tablets. 
• 2017: Approval and launch of Clonidine Hydrochloride extended release tablets.
• 2018: Commissioned Ajanta's 1st ever Derma facility in Guwahati.
• 2019: New manufacturing facility for oral solid inaugurated at Pithampur.
  
• 2023: Ajanta Pharma gets USFDA’s final nod for Topiramate Extended-Release Capsules.
• 2023: Ajanta Pharma inks partnership with Credible Innovations.
• 2025: Ajanta Pharma enters into in-licensing agreement with Biocon.
• 2026: Ajanta Pharma incorporates wholly owned subsidiary in Ireland.